| Cadence Pharmaceuticals is recently down $1.45 to $8.10 in pre-opening. Cadence Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act goal date for its Priority Review of the New Drug Application for intravenous acetaminophen by three months. The extended PDUFA goal date is February 12, 2010. Over all option implied volatility of 123 is above its 12-week average of 113. November 10 straddle closed at $2.75, December at $3.60 according to Track Data, suggesting large price movement. :theflyonthewall.com |
Subscribe for More Information